

DAVID VIOLA M. D.

CURRICULUM VITAE

ET

STUDIORUM

DAVID VIOLA M. D.
CURRICULUM VITAE ET STUDIORUM

EDUCATION:

- | | |
|------------------------|---|
| July 1996 | Baccalaureate (“Maturità Scientifica”) (44/60), Liceo Scientifico F. Buonarroti, Pisa |
| 28 September 2005 | Doctor of Medicine Degree University of Pisa (105/110). Graduate Thesis: "Clinico-Pathological Features of Papillary Thyroid Microcarcinoma" |
| 26 November 2010 | Specialty Degree in Endocrinology (110/110 Magna cum Laude). Graduate Thesis: "Prognostic Significance of BRAF Mutation in Thyroid Cancer" Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and Other Thyroid Diseases |
| June 2012-January 2013 | European Society of Endocrinology (ESE) International Endocrine Scholars Programme (IESP) at the “Instituto de Investigaciones Biomédicas - Alberto Sols” (IIB), a center from the Autonomous University of Madrid (UAM) and the Spanish National Research Council (CSIC) |

Foreign Languages: Excellent knowledge of English and Spanish and basic of French

PROFESSIONAL EXPERIENCES:

- | | |
|-----------------------------|--|
| October 2003-September 2005 | Student Fellow at the Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and Other Thyroid Diseases |
|-----------------------------|--|

October 2005-October 2010	Merit-Based Scholarship in Endocrinology and Metabolism at the Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
November - December 2010	Medical Internship in Endocrinology and Metabolism at the Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
1 February 2011-31 January 2012	Carrier-Specific Scholarship of Endocrinology and Metabolism at Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders
1 March 2012-15 June 2012	Carrier-Specific Scholarship of Endocrinology and Metabolism at Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders
16 June 2012-31 January 2013	European Society of Endocrinology (ESE) International Endocrine Scholars Programme (IESP) at the Instituto de Investigaciones Biomédicas “Alberto Sols” (IIB), a center from Universidad Autónoma de Madrid (UAM) and the Spanish National Research Council (CSIC)
February 2013-May 2013	Medical Internship in Endocrinology and Metabolism at the Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders

June 2013-up to now Temporary Clinical and Research Associate in Endocrinology and Metabolism at the Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders

AWARDS:

January 2011 Carrier-Specific Scholarship (n. 219 del 14.12.2010) of Endocrinology and Metabolism at the Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases for research in: “Analysis of the Results of 131-Radioiodine Ablation Therapy in Patients with Differentiated Thyroid Carcinoma”

April 2011 European Society of Endocrinology (ESE) International Endocrine Scholars Programme (IESP)

June 2011 Winner of “Outstanding Abstract Award for exceptional research presented at the 93rd Annual Meeting and Expo of The Endocrine Society”. Boston, MA (USA) June 4-7, 2011.

September 2011 Winner of “The ETA Max Pierre König Poster Award sponsored by European Thyroid Association” presented at 35th Annual Meeting of the European Thyroid Association, Krakow, Poland, 10th-14th September 2011.

October 2011 Winner of best poster presented at I Congresso Nazionale di Endocrinologia Oncologica Roma, 26-28 Ottobre 2011.

March 2012 Carrier-Specific Scholarship of Endocrinology and Metabolism at the Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders for research in: “Analysis of the Results of 131-Radioiodine Ablation Therapy in Patients with Differentiated Thyroid Carcinoma”

- June 2013 Winner of “Outstanding Abstract Award for exceptional research presented at the 95th Annual Meeting and Expo of The Endocrine Society”. San Francisco, CA (USA) June 15-18, 2013.
- April 2016 Winner of “Best of JCEM 2015”. 98th Annual Meeting and Expo of The Endocrine Society Boston, MA (USA) April 1-4, 2016.
- May 2018 Winner of best poster presented at Incontri Italiani di Endocrinologia e Metabolismo, 10-11 Maggio 2018, Bari. Title: recidiva di carcinoma tiroideo diagnosticato con l’aumento del titolo anticorpale (AbTg) dopo 10 anni dal trattamento iniziale

TEACHING:

- 11-15th April 2011 Lecturer in the “Training Course on Differentiated Thyroid Cancer Management” (Sponsor: Genzyme) at Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
- 23-27th May 2011 Lecturer in the “Training Course on Differentiated Thyroid Cancer Management” (Sponsor: Genzyme) at Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
- 16-20th April 2012 Lecturer in the “Training Course on Differentiated Thyroid Cancer Management” (Sponsor: Genzyme) at Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
- 15-19th April 2013 Lecturer in the “Training Course on Differentiated Thyroid Cancer Management” (Sponsor: Genzyme) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases

16-20 th September 2013	Lecturer in the “Training Course on Differentiated Thyroid Cancer Management” (Sponsor: Genzyme) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
3-4 th April 2014	Lecturer in the “Training Course on Rairefractory thyroid tumors Management” (Sponsor: Bayer) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
23-24 th April 2014	Lecturer in the “Training Course on Rairefractory thyroid tumors Management” (Sponsor: Bayer) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
20-24 th April 2015	Lecturer in the “Training Course on Rairefractory thyroid tumors Management” (Sponsor: Bayer) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
9-14 th April 2016	Lecturer in the “Training Course on Rairefractory thyroid tumors Management” (Sponsor: Bayer) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases
8-12 th May 2017	Lecturer in the “Training Course on Rairefractory thyroid tumors Management” (Sponsor: Bayer) at Department of Clinical and Experimental Medicine, University of Pisa, WHO Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and other Thyroid Diseases

INVESTIGATOR IN CLINICAL TRIALS:

Vandetanib (ZD6474)*	“An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (Zactima®) Versus Placebo In Subjects with Unresectable, Locally Advanced or
-----------------------------	---

Metastatic Medullary Thyroid Cancer”. NCT00410761. (Sponsor: AstraZeneca)

Cabozantinib (XL184)*	“An International, Randomized, Double-Blinded, Phase III, Efficacy Study of XL-184 Versus Placebo In Subjects With Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer”. NCT00704730. (Sponsor: Exelixis, Inc.)
Selumetinib (AZD6244)	“A Randomized, Double-Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and a Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer”. NCT01843062 (Sponsor: AstraZeneca)
Cabozantinib (XL184)	“A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/day Compared to 140 mg/day in Progressive, Metastatic Medullary Thyroid Cancer Patients” NCT01896479. (Sponsor: Exelixis, Inc.)
Cabozantinib (XL184)	“A study of Cabozantinib Compared with Placebo in Subject with Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy” NCT03690388. (Sponsor: Exelixis, Inc.)
Selpercatinib (LOXO292)	“A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)” NCT03906331. (Sponsor: Loxo Oncology/Eli Lilly and Co.)
Selpercatinib (LOXO292)	“A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer” (LIBRETTO-531) (J2G-MC-JZJB). NCT04211337. (Sponsor: Eli Lilly and Co.)

*For the above mentioned trials we successfully managed FDA inspections

INVITED SPEAKER AT NATIONAL AND INTERNATIONAL CONFERENCES:

1. Long Term Outcomes of Patients Undergoing Ablation With Low Activities of RAI. Advances in Thyroid Cancer Meeting. June 7th 2014, Istanbul, Turkey.

2. Tyrosine kinase inhibitors for the treatment of thyroid cancer. International Thyroid Cancer Conference. 18th October 2014, Tirana, Albania.
3. New perspectives in the management of thyroid cancer patients. The 10th International Congress of Endocrine Disorders. 22-24th October 2014, Shahid Beheshti University International Conference Center, Teheran, Iran.
4. Thyroid Cancer: 1st Middle East and North Africa Leadership Forum. 12-13 June 2015, Hilton Bomonti Conference Center, Istanbul, Turkey. Radioiodine ablation: who and how should be treated.
5. Thyroid Cancer: 1st Middle East and North Africa Leadership Forum. 12-13 June 2015, Hilton Bomonti Conference Center, Istanbul, Turkey. Follow-up of differentiated thyroid carcinoma.
6. II Workshop: le patologie endocrino-metaboliche – approccio clinico-chirurgico e nuovi orizzonti terapeutici. 26 June 2015, Campobasso, Italy. Il carcinoma tiroideo metastatico: nuovi orizzonti terapeutici.
7. V Conference of Thyroid Cancer and other Malignant Tumors of the Endocrine System 14-17 November 2015, Wisla, Poland. Tyrosine Kinase Inhibitors in the Treatment of Radioiodine Resistant Differentiated Thyroid Cancer.
8. VI Advanced Course of Endocrinology. 16th April 2016, Congress Centre of Porto Palacio Hotel. Oporto, Portugal. Advances in the Management of Radioiodine-Refractory Thyroid Carcinoma.
9. VI European Conference on cured and chronic cancer patients - September, 23-24th 2016, Siracusa.
10. Gestione e trattamento dei tumori refrattari alle terapie convenzionali - May, 19th 2017, Bolzano
11. Advances in treatment of medullary thyroid carcinoma. Endo-Ern: Rare Endocrine Diseases. 22-23 September 2017, Padova.
12. 15th Annual Meeting of Middle East Academy of Otolaryngology and Head and Neck Surgery. 2nd Middle East Thyroid Cancer Conference. 1-3 April 2018, Dubai. Two lectures: “radioiodine refractory thyroid cancer”; “new trend in radioiodine ablation”.
13. Decimo Simposio Ostunense di Medicina Oncologica, 24/11/2018 Ostuni: “Carcinoma tiroideo”.
14. IX Advanced Course of Endocrinology. 5th-6th April 2019, Congress Centre of Porto Palacio Hotel. Oporto, Portugal. Medullary Thyroid Carcinoma: Medical Management.

CERTIFICATES

- **July 1996** First Certificate in English, Oxford University (Common European Framework of Reference for Languages: B2)
- **January 2013** Certificate of Spanish language (Common European Framework of Reference for Languages: B1)

- **July 2013** Investigator Site Personnel ICH GCP Training Certificate: “Minimum Criteria for ICH E6 GCP Investigator Site Personnel Training,” identified by TransCelerate BioPharma, Inc.; International Conference on Harmonisation E6 Good Clinical Practice (ICH GCP) Investigators Training
- **September 2013** Basic Thyroid Course on “Thyroid development, function and carcinogenesis”, European Thyroid Association
- **November 2013** “Basic Life Support, Associazione Nazionale Medici Cardiologi Ospedalieri – American Heart Association”
- **November 2013** Introduction to the Clinical Drug Development Process: ICH Good Clinical Practice for Clinical Trial Sites (7 modules, Qintiles Inc.)

MEMBERSHIPS:

2005- up to now	Ordinary Member of the Italian Society of Endocrinology
2006- up to now	Ordinary Member of the Ex-Allievi Endocrinologia Pisana
2006- up to now	Ordinary Member of the Italian Association of the Thyroid
2011- up to now	Lifetime Member of the European Society of Endocrinology
2011- up to now	Ordinary Member of the European Thyroid Association
2016- up to now	Ordinary Member of The Endocrine Society

REFEREE:

- Journal of Clinical Endocrinology and Metabolism
- Endocrine Related Cancer
- Thyroid
- Oncotarget
- Expert Opinion On Pharmacotherapy
- European Journal of Cancer
- International Journal of Endocrine Oncology

CONSULTANCIES/ADVISORY BOARD:

- Swedish Orphan Biovitrum AB (SOBI)
 1. Current Treatment Practices of Medullary Thyroid Cancer (MTC) and the potential of Cometriq in the European MTC Therapy Landscape. Amsterdam, 29 September 2013.
- Genzyme, a Sanofi Company:
 1. European Advisory Board on Thyroid Cancer Management. Delayed Risk Stratification. Treatment of non-RAI-avid metastasis. Frankfurt, 7th November 2015.
 2. Thyroid Cancer Management - European DTC Advisory Board 2016. Amsterdam, 11th June 2016.

3. Controversies on differentiated thyroid cancer management. MED-NET TV/Web TV; Springer Healthcare. Amsterdam, 13/12/2017.
4. Burning questions on Medullary Thyroid Cancer management. MED-NET TV/Web TV; Springer Healthcare. Amsterdam, 14/12/2017.
5. Larotrectinb advisory board for patients with thyroid cancer TRK mutations. New York, New York, Saturday March 23, 2019.

RESEARCH INTERESTS:

- Thyroid Carcinogenesis
- Oncogenes: clinical/prognostic implications
- Experimental Clinical Trials
- Tyrosine Kinase Inhibitors
- Medullary thyroid Carcinoma, RET genetic screening and Multiple Endocrine Neoplasia

EDITORIAL ACTIVITY:

- Editor of Reproductive System & Sexual Disorders International Journal
- Editor of Science Technology Medicine (SciTeMed) Publishing Group
- Associate Editor of International Journal of Endocrinology & Metabolism
- Associate Editor of Current Research in Diabetes & Obesity Journal

DAVID VIOLA M. D.

SCIENTIFIC PUBLICATIONS
(2008-2021)

A Total of **196** Publications:

51 Papers Published in International Peer-Reviewed Journals

140 Manuscripts in Proceedings of National and International Meetings and Book Chapters

SCIENTIFIC PUBLICATIONS

DAVID VIOLA M. D.

(2008-2021)

Papers Published in International Peer-Reviewed Journals

1. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Elisei R, Ugolini C, **Viola D**, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9.
2. Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. Miccoli P, Pinchera A, Materazzi G, Biagini A, Berti P, Faviana P, Molinaro E, **Viola D**, Elisei R. J Clin Endocrinol Metab. 2009 May;94(5):1618-22.
3. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. Molinaro E, **Viola D**, Passannanti P, Agate L, Lippi F, Ceccarelli C, Pinchera A, Elisei R. Q J Nucl Med Mol Imaging. 2009 Oct;53(5):490-502.
4. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, **Viola D**, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P, Elisei R. Clin Endocrinol (Oxf). 2011 Feb;74(2):241-7.
5. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, Cappagli V, **Viola D**, Piaggi P, Vitti P, Pinchera A, Elisei R. Endocr Relat Cancer. 2011 Sep 20;18(5):603-12.
6. An idic(15) associated with POF (premature ovarian failure): molecular cytogenetic definition of a case and review of the literature. Bertini V, **Viola D**, Vitti P, Simi P, Valetto A. Gene. 2012 Jul 15;503(1):123-5.
7. Modifications in the papillary thyroid cancer gene profile over the last 15 years. Romei C, Fugazzola L, Puxeddu E, Frasca F, **Viola D**, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R. J Clin Endocrinol Metab. 2012 Sep;97(9):E1758-65.
8. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. Molinaro E, Pieruzzi L, **Viola D**. J Endocrinol Invest. 2012;35(6 Suppl):16-20. Review.
9. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort

- study. Elisei R, **Viola D**, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F. J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8.
10. Incidental versus clinically evident thyroid cancer: a 5-year follow-up study. Minuto MN, Miccoli M, **Viola D**, Ugolini C, Giannini R, Torregrossa L, Antonangeli L, Aghini-Lombardi F, Elisei R, Basolo F, Miccoli P. Head Neck. 2013 Mar;35(3):408-12.
 11. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Xing M, Alzahrani AS, Carson KA, **Viola D**, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. JAMA. 2013 Apr 10;309(14):1493-501.
 12. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, **Viola D**, Piaggi P, Vitti P, Pacini F, Elisei R. J Clin Endocrinol Metab. 2013; 98(7):2693-700.
 13. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. **Viola D**, Cappagli V, Elisei R. Future Oncol. 2013 Aug;9(8):1083-92.
 14. FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to ¹³¹-iodine treatment. Ugolini C, Elisei R, Proietti A, Pelliccioni S, Lupi C, Borrelli N, **Viola D**, Leocata P, Vitti P, Miccoli P, Toniolo A, Basolo F. Thyroid. 2014 Feb;24(2):339-46.
 15. How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. Elisei R, Agate L, **Viola D**, Matrone A, Biagini A, Molinaro E. Endocrinol Metab Clin North Am. 2014 Jun;43(2):331-344.
 16. Medullary thyroid carcinoma in children. **Viola D**, Romei C, Elisei R. Endocr Dev. 2014;26:202-13.
 17. Association between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. Xing M, Alzahrani AS, Kathryn A, Carson KA, Shong YK, Kim TY, **Viola D**, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sykorova V. J Clin Oncol. 2015 Jan 1;33(1):42-50.
 18. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Romei C, Tacito A, Molinaro E, Agate L, Bottici V, **Viola D**, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R. Clin Endocrinol. 2015 Jun;82(6):892-9.
 19. Prophylactic Central Compartment Lymph Node Dissection In Papillary Thyroid Carcinoma: Clinical Implications Derived From The First Prospective Randomized Controlled Single Institution Study.

- Viola D**, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, and Miccoli P. *J Clin Endocrinol Metab*. 2015 Apr;100(4):1316-24.
20. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Kee Shong Y, Yong Kim T, Cheng S, Asa SL, **Viola D**, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M. *J Clin Endocrinol Metab*. 2016 Jan;101(1):264-74.
 21. Treatment Of Advanced Thyroid Cancer With Targeted Therapies: Ten Years Of Experience. **Viola D**, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati P, Puleo P, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo S, Vitti P, Elisei R. *Endocr Relat Cancer*. 2016 Apr;23(4):R185-205.
 22. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. Romei C, Casella F, Tacito A, Bottici V, Valerio L, **Viola D**, Cappagli V, Matrone A, Ciampi R, Piaggi P, Ugolini C, Torregrossa L, Basolo F, Materazzi G, Vitti P, Elisei R. *J Med Genet*. 2016 Jul 28.
 23. Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. Torregrossa L, **Viola D**, Sensi E, Giordano M, Piaggi P, Romei C, Materazzi G, Miccoli P, Elisei R and Basolo F. *J Clin Endocrinol Metab*. 2016 Nov;101(11):4413-4420.
 24. Papillary thyroid microcarcinoma and active surveillance. **Viola D**. *Lancet Diabetes Endocrinol*. 2016 Dec;4(12):975.
 25. Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131-I ablation. Matrone A, Gambale C, Piaggi P, **Viola D**, Giani C, Agate L, Bottici V, Bianchi F, Materazzi G, Vitti P, Molinaro E, Elisei R. *J Clin Endocrinol Metab*. 2017 Mar 1;102(3):893-902.
 26. Targeted Therapy in Thyroid Cancer: State of the Art. Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, Cappagli V, Puleo L, Matrone A, **Viola D**, Romei C, Ciampi R, Molinaro E, Elisei R. *Clin Oncol (R Coll Radiol)*. 2017 May;29(5):316-324.
 27. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, **Viola D**, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Liu S, Zhao J, Zhao S, Xing M. *J Clin Endocrinol Metab*. 2017 Sep 1;102(9):3241-3250.
 28. Role of YAP-1 in Thyroid Tumor Progression and Outcome. Ugolini C, Borrelli N, Niccoli C, Elisei R, **Viola D**, Vitti P, Miccoli P, Basolo F. *Appl Immunohistochem Mol Morphol*. 2017 Sep;25(8):581-585.

29. KIF5B/RET rearrangement in a carcinoma of the thyroid gland: a case report of a fatal disease. **Viola D**, Giani C, Mazzeo S, Ugolini C, Ciampi R, Molinaro E, Agate L, Borrelli N, Pieruzzi L, Chella A, Fontanini G, Basolo F, Elisei R. *J Clin Endocrinol Metab*. 2017 Sep 1;102(9):3091-3096.
30. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, **Viola D**, Del Re M, Molinaro E, Danesi R, Elisei R. *Best Practice & Research: Clinical Endocrinology & Metabolism* 2017 Jun;31(3):319-334
31. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, **Viola D**, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Xing M, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V. *J Natl Cancer Inst*. 2017 Nov 18.
32. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, **Viola D**, Frara S, Berruti A, Giustina A, Giubbini R. *Endocrine*. 2018 Jan;59(1):90-101
33. Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. Shen X, Zhu G, Liu R, **Viola D**, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M. *J Clin Oncol*. 2018 Feb 10;36(5):438-445.
34. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. Romei C, Tacito A, Molinaro E, Piaggi P, Cappagli V, Pieruzzi L, Matrone A, **Viola D**, Agate L, Torregrossa L, Ugolini C, Basolo F, De Napoli L, Curcio M, Ciampi R, Materazzi G, Vitti P, Elisei R. *Oncology letters* 2018.
35. BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Wang F, Zhao S, Shen X, Zhu G, Liu R, **Viola D**, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Xing M. *J Clin Oncol*. 2018 Sep 20;36(27):2787-2795.
36. Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. **Viola D**, Agate L, Molinaro E, Bottici V, Lorusso L, Latrofa F, Torregrossa L, Boldrini L, Ramone T, Vitti P and Elisei R (2018). *Front Endocrinol (Lausanne)*. 2018 Oct 9;9:590.
37. Management of Medullary Thyroid Cancer. **Viola D**, Elisei R. *Endocrinol Metab Clin North Am*. 2019 Mar;48(1):285-301.

38. Fifty years after the first description, the MEN 2B syndrome diagnosis is still late: description of two recent cases. Elisei R, Matrone A, Valerio L, Molinaro E, Agate L, Bottici V, **Viola D**, Giani C, Cappagli V, Latrofa F, Materazzi G, Torregrossa L, Ugolini C, Basolo F, Romei C. *J Clin Endocrinol Metab*. 2019 Jul 1;104(7):2520-2526.
39. Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. Laura Agate, Francesca Bianchi, Federica Brozzi, Pierina Santini, Eleonora Molinaro, Valeria Bottici, **David Viola**, Loredana Lorusso, Paolo Vitti and Rossella Elisei. *Eur Thyroid J* 2019 Apr;8(2):90-95.
40. Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease. Toulis KA, **Viola D**, Gkoutos G, Keerthy D, Boelaert K, Nirantharakumar K. *Clin Endocrinol (Oxf)*. 2019 Aug;91(2):323-330.
41. Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, Bottici V, **Viola D**, Torregrossa L, Ugolini C, Basolo F, Elisei R. *Genetic iScience*. 2019 Oct 25;20:324-336.
42. Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. Molinaro E, **Viola D**, Viola N, Falcetta P, Orsolini F, Torregrossa L, Vagli P, Ribechini A, Materazzi G, Vitti P, Elisei R. *Case Rep Endocrinol*. 2019 Sep 18;2019:6831237.
43. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center. Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, **Viola D**, Cappagli V, Valerio L, Giani C, Puleo L, Lorusso L, Piaggi P, Torregrossa L, Basolo F, Vitti P, Tuttle RM, Elisei R. *J Clin Endocrinol Metab*. 2019 Oct 25.
44. Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. Elisei R, Tacito A, Ramone T, Ciampi R, Bottici V, Cappagli V, **Viola D**, Matrone A, Lorusso L, Valerio L, Giani C, Campopiano C, Prete A, Agate L, Molinaro E, Romei C. *Genes (Basel)*. 2019 Sep 10;10(9).
45. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Kim KJ, Kim SG, Tan J, Shen X, **Viola D**, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M. *Eur J Cancer*. 2020 Jan;124:161-169.
46. Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response. Valerio L, Bottici V, Matrone A, Piaggi P, **Viola D**, Cappagli V, Agate L, Molinaro E, Ciampi R, Tacito A, Ramone T, Romei C, Elisei R. *Endocr Relat Cancer*. 2020 Jan 20;27(2):97-110.
47. Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up. *Endocrine*. Giani C, Torregrossa L, Piaggi P, Matrone A, **Viola D**, Molinaro E, Agate L, Romei C, Ugolini C, De Napoli L, Materazzi G, Basolo F, Elisei R. 2020 Jun;68(3):607-616.

48. Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. De Napoli L, Matrone A, Favilla K, Piaggi P, Galleri D, Ambrosini CE, Aghababayan A, Papini P, Valerio L, **Viola D**, Torregrossa L, Ugolini C, Proietti A, Basolo F, Miccoli P, Elisei R, Materazzi G. *Endocr Pract*. 2020 Aug;26(8):807-817.
49. Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. Matrone A, Faranda A, Latrofa F, Gambale C, Stefani Donati D, Molinaro E, Agate L, **Viola D**, Piaggi P, Torregrossa L, Basolo F, Elisei R. *J Clin Endocrinol Metab*. 2020 Aug 1;105(8):dgaa297.
50. No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH. Campopiano MC, Podestà D, Bianchi F, Giani C, Agate L, Bottici V, Cappagli V, Lorusso L, Matrone A, Puleo L, Valerio L, **Viola D**, Piaggi P, Elisei R, Molinaro E. *Eur J Endocrinol*. 2020 Oct;183(4):411-417.
51. Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. Lorusso L, Romei C, Piaggi P, Fustini C, Molinaro E, Agate L, Bottici V, **Viola D**, Pellegrini G, Elisei R. *Thyroid*. 2021 Jan 7. doi:10.1089/thy.2020.0060. Epub ahead of print. PMID: 33234054.
52. Proteinuria is a late-onset adverse event in patients treated with cabozantinib. Cappagli V, Moriconi D, Bonadio AG, Giannese D, La Manna G, Egidi MF, Comai G, Vischini G, Bottici V, Elisei R, **Viola D**. *J Endocrinol Invest*. 2021 Jan;44(1):95-103.

Manuscripts in Proceedings of National and International Meetings
and Book Chapters

1. Biological and molecular markers for diagnosis, follow-up and prognosis of patients affected by thyroid cancer. R. Elisei, **D. Viola**, A. Pinchera. Eurocancer 2008, John Libbey Eurotext, Paris, 2008, pag. 391-392.
2. La tiroide come sede di metastasi. E. Benelli, **D. Viola**, E. Fiore, C. Giani. L'Endocrinologo, vol. 8 N. 1, 2008, pag 37-38.
3. TSH umano ricombinante nell'ablazione del residuo tiroideo post-chirurgico. R. Elisei, **D. Viola**, A. Pinchera. L'Endocrinologo, vol. 9 suppl. 3, 2008, pag. 26-32.
4. Nuove indicazioni all'impiego del TSH umano ricombinante (rhTSH) e basse attività di ¹³¹I nella radioablazione del residuo tiroideo post-chirurgico. E. Molinaro, C. Giani, L. Agate, A Biagini, L. Pieruzzi, F. Bianchi, F. Brozzi, **D. Viola**, C. Ceccarelli, R. Elisei. L'Endocrinologo, vol. 14, issue 6, 2013, pag 255-260.
5. Targeted therapies for thyroid cancer. **D. Viola** and R. Elisei. Thyroid International 4/2013. Merck KGaA, Darmstadt, Germany.
http://www.thyrolink.com/merck_serono_thyrolink/en/images/Thyroid_inter_4_2013_WEB_tcm1553_121591.pdf?Version=
6. Il carcinoma tiroideo: nuove prospettive terapeutiche. **Viola David**, Laura Agate, Eleonora Molinaro, Valeria Bottici, Loredana Lorusso, Laura Valerio, Antonio Matrone, Agnese Biagini, Virginia Cappagli, Carlotta Giani, Letizia Pieruzzi, Benedetta Pontillo Contillo, Valentina Battaglia, Salvatore Mazzeo and Rossella Elisei. L'Endocrinologo February 2014, Volume 15, Issue 1, pp 28-35. Springer International Publishing. DOI: 10.1007/s40619-014-0017-x.
7. Ret Oncogene and Thyroid Carcinoma. Elisei R, Molinaro E, Agate L, Bottici V, **Viola D**, Biagini A, Matrone A, Tacito A, Ciampi R, Vivaldi A and Romei C. J Genet Syndr Gene Ther 2014, 5:1 <http://dx.doi.org/10.4172/2157-7412.1000214>.
8. Tyrosine Kinase Inhibitors for the Treatment of Thyroid Cancer: Present and Future. **David Viola** and Rossella Elisei. Endocrinol Metab Int J 2(4): 00026. DOI: 10.15406/emij.2015.02.00026.
9. Thyroid cancer: is really less more? Konstantinos A Toulis, Concepción Conchillo Fernández, **Viola D**. Endocrinol Metab Int J 2016; 3(3): 00046. DOI: 10.15406/emij.2016.03.00046
10. Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato. E. Sabini A. Matrone, L. Valerio, C. Giani, L. Pieruzzi, E. Molinaro, **D. Viola**, L. Agate, D. Volterrani, S. Mazzeo, P. Vitti, R. Elisei. L'Endocrinologo, vol. 17, Issue 5, 2016, pag. 266-267.

Abstracts:

1. Small papillary thyroid carcinoma: good biological behaviour of intrathyroidal MPTC. L. Agate, **D. Viola**, M. Sculli, MG. Castagna, C. Ceccarelli, E. Molinaro, R. Lari, F. Basolo, P. Miccoli, A. Pinchera, R. Elisei. 13th International Thyroid Congress, Buenos Aires, October 30-November 4, 2005. *Thyroid* 15 (Suppl. 1), 2005.
2. Clinical and biological features of thyroid microcarcinoma: a series of 793 cases. L. Agate, **D. Viola**, M.A. Sculli, M.G. Castagna, C. Ceccarelli, E. Molinaro, R. Lari, F. Basolo, P. Miccoli, F. Pacini, A. Pinchera, R. Elisei. XXVI Giornate Endocrinologiche Pisane, Pisa, 8-10 Giugno, 2006. *J. Endocrinol. Invest.* 29 (Suppl. 4), 2006.
3. Tissue and blood oncofibronection mRNA as marker of primary and metastatic papillary thyroid cancer. Piampiani P, Vivaldi A, Romei C, Cosci B, Ciampi R, **Viola D**, Agate L, Giannini R, Basolo F, Pinchera A, Elisei R. XXVI Giornate Endocrinologiche Pisane, Pisa, 8-10 Giugno 2006. *J. Endocrinol. Invest.* 29 (Suppl. 4), 2006.
4. Differentiated thyroid carcinoma: are clinical and pathological features changing? P. Passannanti, M.A. Sculli, V. Bottici, R. Lari, E. Molinaro, L. Agate, **D. Viola**, M. Capezzone, P. Miccoli, F. Basolo, F. Pacini, A. Pinchera, R. Elisei. XXVI Giornate Endocrinologiche Pisane, Pisa, 8-10 Giugno 2006. *J. Endocrinol. Invest.* 29 (Suppl. 4), 2006.
5. Infertility in a patient with papillary thyroid carcinoma treated with high doses of 131-I. **D. Viola**, D. Canale, P. Passannanti, C. Cagliaresi, C. Moschini, R. Elisei, E. Martino, A. Pinchera, E. Macchia. XXVI Giornate Endocrinologiche Pisane, Pisa, 8-10 Giugno 2006. *J. Endocrinol. Invest.* 29 (Suppl. 4), 2006.
6. A high rate of cured familial medullary thyroid carcinoma is obtained when combining serum calcitonin and RET gene mutations screenings. G. Renzini, C. Romei, B. Cosci, V. Bottici, M.A. Sculli, E. Molinaro, L. Agate, **D. Viola**, F. Luchetti, L. Grasso, P. Berti, P. Faviana, A. Pinchera, R. Elisei. XXVI Giornate Endocrinologiche Pisane, Pisa, 8-10 Giugno 2006. *J. Endocrinol. Invest.* 29 (Suppl. 4), 2006.
7. New features of differentiated thyroid carcinoma diagnosed in the last 15 years. P. Passannanti, M.A. Sculli, V. Bottici, R. Lari, E. Molinaro, L. Agate, **D. Viola**, M. Capezzone, P. Miccoli, F. Basolo, F. Pacini, A. Pinchera, R. Elisei. 31st European Thyroid Association Annual Meeting, Naples, 2-6 Settembre 2006.
8. Potential use of tissue and blood oncofibronection mRNA for the diagnosis of primary and metastatic differentiated thyroid cancer. Vivaldi A, Piampiani P, Romei C, Cosci B, Ciampi R, **Viola D**, Agate L, Giannini R, Basolo F, Pinchera A, Elisei R. 31st European Thyroid Association Annual Meeting, Naples, 2-6 Settembre 2006.
9. Expression gene profile may be useful for the diagnosis of thyroid malignancies. Piampiani P, Romei C, Cosci B, Vivaldi A, Ciampi R, **Viola D**, Bottici V, Giannini R, Basolo F, Pinchera A, Elisei R. 31st European Thyroid Association Annual Meeting, Naples, September 2-6, 2006.

10. Serum calcitonin and RET gene mutations screenings allows the early diagnosis and cure of patients with familial medullary thyroid carcinoma. G. Renzini, C. Romei, B. Cosci, V. Bottici, M.A. Sculli, E. Molinaro, L. Agate, **D. Viola**, F. Luchetti, L. Grasso, P. Berti, P. Passannanti, P. Faviana, A. Pinchera, R. Elisei. 31st European Thyroid Association Annual Meeting, Naples, 2-6 September, 2006.
11. BRAFV600E mutations but not RET/PTC rearrangements are correlated with a lower expression of NIS mRNA expression in papillary thyroid tumors. R. Elisei, C. Romei, E. Molinaro, P. Piampiani, M. Sculli, **D. Viola**, V. Bottici, A. Pinchera. 77th Annual Meeting of the American Thyroid Association, Phoenix, Arizona, October 11-15, 2006.
12. Utilizzo del profilo di espressione genica per la diagnosi di patologie maligne tiroidee. Piampiani P, Romei C, Cosci B, Vivaldi A, Ciampi R, Agate L, Molinaro E, **Viola D**, Ugolini C, Basolo F, Pinchera A, Elisei R. XXIV Giornate Italiane della Tiroide, Modena, 30 Novembre-2 Dicembre, 2006.
13. Utilità del dosaggio della calcitonina (CT) nel liquido di lavaggio dell'agoaspirato dei noduli tiroidei in pazienti con CT sierica dosabile. G. Renzini, T. Rago, **D. Viola**, B. Cosci, E. Molinaro, L. Grasso, F. Luchetti, P. Vitti, A. Pinchera, R. Elisei. XXIV Giornate Italiane della Tiroide, Modena, 30 Novembre-2 Dicembre, 2006.
14. Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. **D. Viola**, C. Romei, A. Biagini, L. Agate, L. Molinaro, R. Ciampi, G. Renzini, R. Giannini, C. Ugolini, P. Berti, A. Pinchera, R. Elisei. XXIV Giornate Italiane della Tiroide, Modena, 30 Novembre-2 Dicembre, 2006.
15. Expression gene profile may be useful for the diagnosis of thyroid malignancies. Piampiani P, Romei C, Cosci B, Vivaldi A, Ciampi R, **Viola D**, Bottici V, Giannini R, Basolo F, Pinchera A, Elisei R. 9th European Congress of Endocrinology, Budapest, April 28-May 2, 2007. Endocrine Abstracts 14, 2007.
16. . Usefulness of calcitonin (CT) measurement in wash-out fluid from fine needle aspiration biopsy in thyroid nodules of patients with detectable serum CT. G. Renzini, T. Rago, P. Passannanti, **D. Viola**, B. Cosci, E. Molinaro, L. Grasso, F. Lucchetti, P. Vitti, A. Pinchera & R. Elisei 9th European Congress of Endocrinology, Budapest, April 28-May 2, 2007. Endocrine Abstracts 14, 2007.
17. Prognostic significance of BRAF mutation in patients affected by papillary thyroid carcinoma with a follow up of 20 years. **D. Viola**, C. Romei, A. Biagini, L. Agate, E. Molinaro, R. Ciampi, G. Renzini, R. Giannini, C. Ugolini, P. Berti, A. Pinchera & R. Elisei. 9th European Congress of Endocrinology, Budapest, April 28-May 2, 2007. Endocrine Abstracts 14, 2007.
18. Expression gene profile may be useful for the diagnosis of thyroid malignancies. Piampiani P, Romei C, Cosci B, Vivaldi A, Ciampi R, **Viola D**, Bottici V, Giannini R, Basolo F, Pinchera A, Elisei R. 89^o Congress of the Endocrine Society, Toronto, June 2-5, 2007.

19. BRAF^{V600E} mutation is an independent bad prognostic factor for the out come of patients with papillary thyroid carcinoma: a 15-year median follow-up study. **David Viola**, Clara Ugolini, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera, Fulvio Basolo, Rossella Elisei. 7th European Thyroid Association - Cancer Research Network Meeting, Leipzig, 1st September 2007.
20. BRAF^{V600E} mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC). C. Romei, R. Ciampi, P. Faviana, F. Basolo, V. Bottici, **D. Viola**, P. Berti, E. Molinaro, A. Pinchera, R. Elisei. 32nd European Thyroid Association Annual Meeting, Leipzig, September 1-5, 2007. Hormone Research 68 (Suppl. 3), 2007.
21. Expression Gene Profile May Be Useful For The Diagnosis of Thyroid Malignancies. Piampiani P, Romei C, Cosci B, Vivaldi A, Ciampi R, **Viola D**, Bottici V, Giannini R, Basolo F, Pinchera A, Elisei R. 7th European Thyroid Association - Cancer Research Network Meeting, Leipzig, 1st September 2007.
22. Prognostic role of BRAF^{V600E} mutation in papillary thyroid carcinoma. **D. Viola**, C. Ugolini, C. Lupi, A Biagini, R. Giannini, C. Romei, P. Miccoli, A. Pinchera, F. Basolo, R. Elisei. XXVII Giornate Endocrinologiche Pisane, Pisa, 26-28 Giugno, 2008. J. Endocrinol. Invest 2008, vol. 31 (Suppl. 4).
23. BRAF^{V600E} mutation is an independent bad prognostic factor for the outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. **David Viola**, Clara Ugolini, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera, Fulvio Basolo, Rossella Elisei. 33rd European Thyroid Association Annual Meeting, Thessaloniki-Chalkidiki, September 20-24, 2008. Hormones 7 (Suppl. 1), 2008.
24. Can the result of the second recombinant human thyrotropin stimulated thyroglobulin test be predicted? Biagini A, Passannanti P, Molinaro E, **Viola D**, Taddei D, Grasso L, Pinchera A, Elisei R. 33rd European Thyroid Association Annual Meeting, Thessaloniki-Chalkidiki, September 20-24, 2008. Hormones 7 (Suppl. 1), 2008.
25. Il dosaggio della calcitonina sierica nei pazienti con nodulo tiroideo identifica il carcinoma midollare ad uno stadio più precoce e ne favorisce la guarigione. Renzini G, Bottici V, **Viola D**, Passannanti P, Romei C, Pinchera A, Elisei R. XXVI Giornate Italiane della Tiroide, Aosta, 3-5 Dicembre, 2008.
26. Clinical relevance of low levels of serum peak Tg at the recombinant TSH stimulation test (rhTSH). A Biagini, E. Molinaro, P. Passannanti, **D. Viola**, L. Agate, D Taddei, L. Grasso, A. Pinchera, R. Elisei. XXXIII National Congress of the Italian Society of Endocrinology, Sorrento, May 27-30, 2009. J. Endocrinol. Invest, vol. 32 (Suppl. 2), 2009.
27. Spontaneous experimental trial with sorafenib (off-label use) in patients with metastatic thyroid cancer not more responsive to conventional therapies. V. Bottici, P. Passannanti, E. Molinaro, L. Agate, A Biagini, **D. Viola**, L. Dal Canto, S. Mazzeo, V. Battaglia, A. Pinchera, R. Elisei. XXXIII National Congress of the Italian Society of Endocrinology, Sorrento, May 27-30, 2009. J. Endocrinol. Invest, vol. 32 (Suppl. 2), 2009.

28. Off-label use of sorafenib in patients with metastatic thyroid cancer unresponsive to conventional therapies, a spontaneous study. P. Passannanti, V. Bottici, E. Molinaro, L. Agate, B. Biagini, **D. Viola**, L. Dal Canto, S. Mazzeo, V. Battaglia, A. Pinchera, R. Elisei. 34th European Thyroid Association Annual Meeting, Lisbon, September 5-9, 2009. Acta Med Port vol. 22, 2009.
29. Serum measurement is the most important diagnostic tool for the early diagnosis and the cure of medullary thyroid cancer. G. Renzini, V. Bottici, P. Passannanti, **D. Viola**, C. Romei, B. Cosci, F. Pacini, A. Pinchera, R. Elisei. 34th European Thyroid Association Annual Meeting, Lisbon, September 5-9, 2009. Acta Med Port vol. 22, 2009.
30. Is incidental thyroid cancer different from the clinically evident one? A 5-years follow-up study. M. Minuto, M. Miccoli, E. Molinaro, R. Giannini, L. Torregrossa, C. Ugolini, F. Basolo, **D. Viola**, L. Antonangeli, R. Elisei, F. Aghini-Lombardi, P. Miccoli. XXXIV National Congress of the Italian Society of Endocrinology, Pisa, June 10-12, 2010. J. Endocrinol. Invest, vol. 33 (Suppl. 4), 2010.
31. Reassessment of clinical features of patients with multiple endocrine neoplasia type 2 syndromes. G. Renzini, V. Bottici, C. Romei, B. Cosci, **D. Viola**, A. Pinchera, R. Elisei. XXXIV National Congress of the Italian Society of Endocrinology, Pisa, June 10-12, 2010. J. Endocrinol. Invest, vol. 33 (Suppl. 4), 2010.
32. Is incidental thyroid cancer different from the clinically evident one? A 5-years follow-up study. M. N. Minuto, M. Miccoli, **D. Viola**, R. Giannini, L. Torregrossa, C. Ugolini, L. Antonangeli, F. Basolo, F. Aghini-Lombardi, R. Elisei, P. Miccoli. 14th International Thyroid Congress, Paris, September 11-16, 2010.
33. Short term follow-up outcome of stage I thyroid cancer patients is worst when BRAF^{V600E} mutation is present in the primary tumor. **D. Viola**, R. Giannini, C. Ugolini, A. Biagini, F. Basolo, A. Pinchera, R. Elisei. 14th International Thyroid Congress, Paris, September 11-16, 2010.
34. L'impiego di un metodo ultrasensibile di dosaggio della Tg nel follow-up di pazienti con carcinoma tiroideo necessita una revisione del cut off di negatività. L. Valerio, D. Taddei, C. Nencetti, E. Molinaro, L. Agate, **D. Viola**, A. Pinchera, L. Grasso, R. Elisei. 4° Congresso della Associazione Italiana della Tiroide e XXVIII Giornate Italiane della Tiroide, Campobasso, 2-4 Dicembre, 2010.
35. . Utilità della ricerca della mutazione di BRAF nel tumore primitivo di pazienti affetti da carcinoma papillare della tiroide a basso rischio. **D. Viola**, R. Giannini, C. Ugolini, A. Biagini, F. Basolo, A. Pinchera, R. Elisei. 4° Congresso della Associazione Italiana della Tiroide e XXVIII Giornate Italiane della Tiroide, Campobasso, 2-4 Dicembre, 2010.
36. Metastatic, aggressive follicular poorly differentiated thyroid cancer (FPDTC) unresponsive to conventional therapy: sunitinib as last resort. V. Cappagli, V. Bottici, E. Molinaro, L. Agate, **D. Viola**, P. Passannanti, A. Biagini, I. Muller, F. Saponaro, S. Mazzeo, L. Dal Canto, P. Vitti, A. Pinchera, R. Elisei. XXXV National Congress of the Italian Society of Endocrinology, Montesilvano (Chieti-Pescara), May 18-21, 2011. J. Endocrinol. Invest. 34 (Suppl. 3), 2011.

37. Radioiodine remnant ablation with low activity of ^{131}I with recombinant TSH or after withdrawal of LT4 therapy: outcome after 10 years of follow up. C. Giani, E. Molinaro, A. Biagini, L. Agate, **D. Viola**, V. Bottici, P. Passannanti, L. Pieruzzi, P. Vitti, A. Pinchera, R. Elisei. XXXV National Congress of the Italian Society of Endocrinology, Montesilvano (Chieti-Pescara), May 18-21, 2011. J. Endocrinol. Invest. 34 (Suppl. 3), 2011.
38. The use of an ultrasensitive thyroglobulin assay in the follow-up of patients with thyroid carcinoma requires a review of its cut-off. L. Valerio, D. Taddei, C. Nencetti, E. Molinaro, L. Agate, V. Bottici, **D. Viola**, P. Vitti, A. Pinchera, L. Grasso, R. Elisei. XXXV National Congress of the Italian Society of Endocrinology, Montesilvano (Chieti-Pescara), May 18-21, 2011. J. Endocrinol. Invest. 34 (Suppl. 3), 2011.
39. Low-Risk Differentiated Thyroid Cancer with BRAF^{V600E} mutation is more difficult to cure than negative cases: a 5-year follow-up study. **D. Viola**, R. Giannini, C. Ugolini, A. Biagini, C. Romei, E. Molinaro, L. Agate, F. Basolo, A. Pinchera, R. Elisei. 93rd Annual Meeting and Expo of The Endocrine Society, Boston, June 4-7, 2011. Endocr Rev Vol. 32.
40. Clinical significance of anti-thyroid antibodies (AT-Ab) titer trend in a long-term follow-up of patients with differentiated thyroid carcinoma (DTC). Lorusso L, Agate L, Latrofa F, Bottici V, Molinaro E, **Viola D**, Grasso L, Pinchera A, Vitti P, Elisei R. 35th Annual Meeting of the European Thyroid Association, Krakow, September 10-14, 2011. European Thyroid Journal 2011.
41. Patients with differentiated thyroid cancer (DTC) who underwent radioiodine remnant ablation (RRA) with low activity of ^{131}I either recombinant human TSH (rhTSH) or after thyroid hormone withdrawal (THW) show the same outcome after 10 years of follow-up. Molinaro E, Giani C, Biagini A, Pieruzzi L, Agate L, Bottici V, **Viola D**, Pinchera A, Vitti P, Elisei R. 35th Annual Meeting of the European Thyroid Association, Krakow, September 10-14, 2011. European Thyroid Journal 2011.
42. Follow-up of differentiated thyroid cancer (DTC) patients defined free of disease with a single negative recombinant human thyrotropine (rhTSH) thyroglobulin (Tg) stimulation test. Biagini A, Pieruzzi L, Molinaro E, Giani C, **Viola D**, Valerio L, Agate L, Bottici V, Pinchera A, Vitti P, Elisei R. 35th Annual Meeting of the European Thyroid Association, Krakow, September 10-14, 2011. European Thyroid Journal 2011.
43. Metastatic thyroid cancer unresponsive to conventional therapy treated with sorafenib “off-label” an update of our experience. Cappagli V, Bottici V, Molinaro E, Agate L, **Viola D**, Valerio L, Mazzeo S, Battaglia V, Pontillo Contillo B, Dal Canto L, Vitti P, Pinchera A, Elisei R. 35th Annual Meeting of the European Thyroid Association, Krakow, September 10-14, 2011. European Thyroid Journal 2011.
44. The use of an ultrasensitive thyroglobulin assay in the follow-up of patients with thyroid carcinoma requires a review of its cut-off. Valerio L, Taddei D, Nencetti C, Molinaro E, Agate L, Lorusso L, Bottici V, **Viola D**, Vitti P, Pinchera A, Grasso L, Elisei R. 35th Annual Meeting of the European Thyroid Association, Krakow, September 10-14, 2011. European Thyroid Journal 2011.

45. Nuovi approcci alla terapia dei tumori tiroidei. Risultati ed efficacia. R. Elisei, E. Molinaro, L. Agate, V. Bottici, P. Passannanti, A. Biagini, **D. Viola**, L. Lorusso, V. Cappagli, L. Valerio, A. Pinchera. Congresso Nazionale AME-6° Congresso Congiunto AME-ANIED, Udine, 14-16 ottobre 2011.
46. Medullary thyroid cancer: from genetic to therapy. R. Elisei, V. Bottici, V. Cappagli, D. Viola, L. Valerio and Pinchera. The 39th Meeting of the International Society of Oncology and BioMarkers, 15-19 October, 2011 Sheraton Congress Center, Firenze, Italy.
47. Significato clinico dell'andamento del titolo degli anticorpi anti-tiroide (AbAT) nel follow-up a lungo termine dei pazienti con carcinoma differenziato della tiroide. Lorusso L, Agate L, Latrofa F, Molinaro E, Bottici V, **Viola D**, Grasso L, Pinchera A, Vitti P, Elisei R. I Congresso Nazionale di Endocrinologia Oncologica, Roma, 26-28 Ottobre 2011.
48. Terapia con sorafenib "off-label" in pazienti con carcinoma tiroideo avanzato e non responsivo alle terapie convenzionali: la nostra esperienza. V. Cappagli, V. Bottici, E. Molinaro, L. Agate, **D. Viola**, L. Valerio, S. Mazzeo, V. Battaglia, B. Postillo Contillo, L. Dal Canto, P. Vitti, A. Pinchera, R. Elisei. 5° Congresso della Associazione Italiana della Tiroide e XXIX Giornate Italiane della Tiroide, Padova, 1-3 Dicembre, 2011.
49. Follow-up di pazienti affetti da carcinoma differenziato della tiroide (DTC) dichiarati in remissione di malattia circa 10 anni fa dopo un singolo test di stimolo per la tireoglobulina (Tg) con TSH umano ricombinante (rhTSH). L. Pieruzzi, A. Biagini, E. Molinaro, C. Giani, **D. Viola**, L. Valerio, L. Agate, V. Bottici, F. Brozzi, A. Pinchera, P. Vitti, R. Elisei. 5° Congresso della Associazione Italiana della Tiroide e XXIX Giornate Italiane della Tiroide, Padova, 1-3 Dicembre, 2011.
50. Un caso di carcinoma midollare della tiroide metastatico non responsivo alla terapia con inibitore tirosino chinasi. V. Bottici, L. Valerio, L. Lorusso, L. Agate, E. Molinaro, P. Passannanti, **D. Viola**, V. Cappagli, P. Vitti, A. Pinchera, R. Elisei. 5° Congresso della Associazione Italiana della Tiroide e XXIX Giornate Italiane della Tiroide, Padova, 1-3 Dicembre, 2011.
51. Pazienti (PZ) con carcinoma differenziato della tiroide (DTC) sottoposti ad ablazione del residuo post-chirurgico (RRA) con 30 mCi di 131-I dopo stimolazione con TSH umano ricombinante (rhTSH) o dopo sospensione della levo-tiroxina (THW): outcome dopo 10 anni di follow-up. C. Giani, E. Molinaro, A. Biagini, L. Pieruzzi, L. Agate, V. Bottici, **D. Viola**, F. Bianchi, P. Piaggi, P. Vitti, A. Pinchera, R. Elisei. 5° Congresso della Associazione Italiana della Tiroide e XXIX Giornate Italiane della Tiroide, Padova, 1-3 Dicembre, 2011.
52. Un caso di MEN 2A associata ad elevati livelli di Ca 19.9. L. Lorusso, L. Agate, E. Molinaro, V. Bottici, P. Passannanti, **D. Viola**, V. Cappagli, L. Valerio, P. Vitti, A. Pinchera, R. Elisei. 5° Congresso della Associazione Italiana della Tiroide e XXIX Giornate Italiane della Tiroide, Padova, 1-3 Dicembre, 2011.
53. An INVDUP(15) associated with premature ovarian insufficiency. **Viola D**, Valetto A, Bertini V, Simi P, Vitti P. 15th International and 14th European Congress of Endocrinology (ICE/ECE), Florence, 5-9 May, 2012. Endocrine Abstracts 29, 2012.

54. BRAF^{V600E} mutation is an independent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. **Viola D**, Torregrossa L, Giannini R, Ugolini C, Bigini A, Romei C, Molinaro E, Agate A, Basolo F, Pinchera A, Vitti P, Elisei E. 15th International and 14th European Congress of Endocrinology (ICE/ECE), Florence, 5-9 May, 2012. Endocrine Abstracts 29, 2012.
55. Rate, time and risk factors for recurrence in patients affected with differentiated thyroid cancer (DTC): a 10 year prospective study. Pieruzzi L, Molinaro E, Giani C, Marconcini G, **Viola D**, Valerio L, Biagini A, Bianchi F, Brozzi F, Taddei D, Nencetti C, Pinchera A, Vitti P, Elisei R. 36th Annual Meeting of The European Thyroid Association, Pisa, September 8-12, 2012. European Thyroid Journal 2012.
56. Papillary thyroid cancer gene profile modification over the last 15 years. Romei C, Fugazzola L, Puxeddu E, Frasca F, **Viola D**, Muzza M, Moretti S, Nicolosi M, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R. 36th Annual Meeting of The European Thyroid Association, Pisa, September 8-12, 2012. European Thyroid Journal 2012.
57. Carbohydrate antigen 19.9 (Ca 19.9): a new poor prognostic factor for the outcome of Medullary Thyroid Cancer (MTC) patients? Lorusso L, Romei C, Bottici V, Agate L, Molinaro E, Cappagli V, **Viola D**, Luchetti F, Grasso L, Pinchera A, Vitti P, Elisei R. 36th Annual Meeting of The European Thyroid Association, Pisa, September 8-12, 2012. European Thyroid Journal 2012.
58. Potential clinical application of oncofetal fibronectin mRNA measurement in tumor tissues and blood of patients with differentiated thyroid tumors. Vivaldi A, Molinaro E, Agate L, Ciampi R, Valerio L, **Viola D**, Pinchera A, Vitti P, Elisei R. 36th Annual Meeting of The European Thyroid Association, Pisa, September 8-12, 2012. European Thyroid Journal 2012.
59. Pros and cons of prophylactic central compartment lymph node dissection in differentiated thyroid cancer patients. Valerio L, **Viola D**, Materazzi G, Miccoli P, Basolo F, Sensi E, Faviana P, Molinaro E, Agate L, Pinchera A, Elisei R. 36th Annual Meeting of The European Thyroid Association, Pisa, September 8-12, 2012. European Thyroid Journal 2012.
60. Metastatic thyroid cancer (TC) unresponsive to conventional therapy and other tyrosine kinases inhibitors (TKI) treated with sunitinib “off-label”. Cappagli V, Bottici V, Molinaro E, Agate L, **Viola D**, Valerio L, Mazzeo S, Battaglia V, Contillo Pontillo B, Dal Canto L, Vitti P, Pinchera A, Elisei R, Ribechini A. 36th Annual Meeting of The European Thyroid Association, Pisa, September 8-12, 2012. European Thyroid Journal 2012.
61. Antigene carboidratico 19.9 (Ca 19.9): nuovo fattore prognostico negativo del carcinoma midollare della tiroide (MTC). L. Lorusso, C. Romei, V. Bottici, L. Agate, E. Molinaro, V. Cappagli, **D. Viola**, F. Luchetti, L. Grasso, P. Vitti, R. Elisei. 6° Congresso della Associazione Italiana della Tiroide e XXX Giornate Italiane della Tiroide, Foggia, 29 Novembre-1 Dicembre, 2012.
62. Valore predittivo della tireoglobulina ultrasensibile al momento dell’ablazione con radioiodio eseguita in eutiroidismo. A. Matrone, C. Gambale, L. Agate, E. Molinaro, V. Bottici, A. Biagini, P.

- Passannanti, **D. Viola**, P. Vitti, R. Elisei. 6° Congresso della Associazione Italiana della Tiroide e XXX Giornate Italiane della Tiroide, Foggia, 29 Novembre-1 Dicembre, 2012.
63. . Pro e contro della linfadenectomia profilattica del compartimento centrale nei pazienti con carcinoma differenziato della tiroide. L. Valerio, **D. Viola**, G. Materazzi, P. Miccoli, F. Basolo, E. Sensi, P. Faviana, E. Molinaro, L. Agate, P. Vitti, R. Elisei. 6° Congresso della Associazione Italiana della Tiroide e XXX Giornate Italiane della Tiroide, Foggia, 29 Novembre-1 Dicembre, 2012.
 64. New insights in the management of differentiated thyroid cancer. Rossella Elisei and **David Viola**. Bulgarian Society of Endocrinology Meeting. Plovdiv, Bulgaria, 11-14 April 2013.
 65. Prophylactic central compartment lymph node dissection does not improve the outcome of patients with a low risk DTC in a short term follow up. L. Valerio, **D. Viola**, G. Materazzi, P. Miccoli, F. Basolo, E. Sensi, P. Faviana, E. Molinaro, L. Agate, R. Elisei. Journal of Endocrinological Investigation. 36th National Congress of the Italian Society of Endocrinology. Padova, June 5-8, 2013.
 66. . Metastatic thyroid cancer (TC) unresponsive to conventional therapy and other thyrosine kinases inhibitors (TKI) treated with sunitinib “off-label”. V. Cappagli, V. Bottici, E. Molinaro, L. Agate, **D. Viola, L. Valerio**, S. Mazzeo, V. Battaglia, B. Contillo Pontillo, L. Dal Canto, A. Ribechini, P. Vitti, R. Elisei. Journal of Endocrinological Investigation. 36th National Congress of the Italian Society of Endocrinology. Padova, June 5-8, 2013.
 67. Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. **D. Viola**, L. Valerio, P. Faviana, E. Molinaro, E. Sensi, L. Agate, G. Materazzi, P. F. Basolo, Miccoli, P. Vitti, R. Elisei. 95rd Annual Meeting and Expo of The Endocrine Society, San Francisco, June 15-18, 2013.
 68. Prophylactic central compartment lymph node dissection (CCND) does not improve the out come of papillary thyroid cancer (PTC) patients: results from the first prospective color study. L. Valerio, **D. Viola**, G. Materazzi, P. Miccoli, F. Basolo, E. Sensi, P. Faviana, E. Molinaro, L. Agate, R. Elisei. European Thyroid Journal. 37th Meeting of the European Thyroid Association. Leiden (The Netherlands), September 7-11, 2013.
 69. Recombinant Human Thyrotropin Stimulation Thyroglobulin (RHTSH-TG) Test can identify false serum Tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients. A. Matrone, C. Gambale, D. Taddei, S. Nencetti, E. Molinaro, L. Agate, V. Bottici, **D. Viola**, P. Vitti, R. Elisei. European Thyroid Journal. 37th Meeting of the European Thyroid Association. Leiden (The Netherlands), September 7-11, 2013.
 70. Vandetanib nel trattamento del carcinoma midollare della tiroide metastatico: esperienza nell’ambito di studi clinici sperimentali di un singolo centro. V. Bottici, L. Valerio, A. Matrone, **D. Viola**, A. Biagini, C. Romei, A. Tacito, S. Mazzeo, V. Battaglia, B. Postillo-Contillo, C. Ugolini, F. Basolo, P. Vitti, R. Elisei. 7° Congresso della Associazione Italiana della Tiroide e XXXI Giornate Italiane della Tiroide, Roma, 5-7 Dicembre, 2013.

71. Il test di stimolo con TSH umano ricombinante (rhTSH Tg test) potrebbe identificare falsi valori di tireoglobulina a causa dell'interferenza di anticorpi esterofili nei pazienti con carcinoma differenziato della tiroide. A. Matrone, C. Gambale, D. Taddei, C. Nencetti, E. Molinaro, L. Agate, V. Bottici, **D. Viola**, P. Vitti, R. Elisei. 7° Congresso della Associazione Italiana della Tiroide e XXXI Giornate Italiane della Tiroide, Roma, 5-7 Dicembre, 2013.
72. Studio prospettico osservazionale monocentrico sull'utilizzo "off-label" del sorafenib in pazienti con carcinoma anaplastico della tiroide. V. Cappagli, E. Sabini, E. Molinaro, V. Bottici, L. Agate, **D. Viola**, A. Biagini, A. Matrone, S. Mazzeo, B. Postillo-Contillo, P. Vitti, R. Elisei. 7° Congresso della Associazione Italiana della Tiroide e XXXI Giornate Italiane della Tiroide, Roma, 5-7 Dicembre, 2013.
73. Impatto clinico dell'analisi genetica di RET nella gestione del paziente con carcinoma midollare della tiroide: 20 anni di esperienza. C. Romei, A. Tacito, R. Ciampi, F. Casella, E. Molinaro, L. Agate, V. Bottici, **D. Viola**, A. Matrone, A. Biagini. Journal of Endocrinological Investigation. 37th National Congress of the Italian Society of Endocrinology and XXXI Giornate Endocrinologiche Pisane. Pisa, April 10-12, 2014.
74. Esperienza nell'uso di Vandetanib in pazienti con carcinoma midollare della tiroide avanzato e correlazione con i dati clinici e molecolari. V. Bottici, L. Valerio, A. Matrone, **D. Viola**, A. Biagini, C. Romei, A. Tacito, S. Mazzeo, V. Battaglia, B. Postillo-Contillo, C. Ugolini, F. Basolo, P. Vitti, R. Elisei. Journal of Endocrinological Investigation. 37th National Congress of the Italian Society of Endocrinology and XXXI Giornate Endocrinologiche Pisane. Pisa, April 10-12, 2014.
75. Studio prospettico osservazionale monocentrico sull'utilizzo "off-label" del sorafenib in pazienti con carcinoma anaplastico della tiroide: aggiornamento dei dati. V. Cappagli, E. Sabini, E. Molinaro, V. Bottici, L. Agate, **D. Viola**, A. Biagini, A. Matrone, S. Mazzeo, B. Postillo-Contillo, P. Vitti, R. Elisei. Journal of Endocrinological Investigation. 37th National Congress of the Italian Society of Endocrinology and XXXI Giornate Endocrinologiche Pisane. Pisa, April 10-12, 2014.
76. L'iperplasia timica come possibile falso positivo di persistenza biochimica di malattia nei pazienti con carcinoma differenziato della tiroide (DTC). A. Matrone, C. Gambale, E. Molinaro, L. Agate, V. Bottici, A. Biagini, **D. Viola**, S. Mazzeo, F. Bianchi, F. Brozzi, P. Vitti, R. Elisei. Journal of Endocrinological Investigation. 37th National Congress of the Italian Society of Endocrinology and XXXI Giornate Endocrinologiche Pisane. Pisa, April 10-12, 2014.
77. Long Term Outcomes of Patients Undergoing Ablation With Low Activities of RAI. **David Viola**. Advances in Thyroid Cancer Meeting. June 7th 2014, Istanbul, Turkey.
78. Predictive value of high sensitive thyroglobulin assay (USTG) and neck ultrasonography (US) at the time of remnant ablation on LT4-therapy in patients with low and intermediate risk differentiated thyroid cancer (DTC). Antonio Matrone, Carla Gambale, Eleonora Molinaro, Laura Agate, Valeria Bottici, Agnese Biagini, **David Viola**, Paolo Vitti, Rossella Elisei. Eur Thyroid J 2014; Oral

- Presentations 3(suppl 1):73-226. 38th Annual Meeting of the European Thyroid Association. Santiago de Compostela, Spain September 6-10, 2014.
79. Follicular (FVTPC) vs classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow-up. Carlotta Giani, Liborio Torregrossa, Eleonora Molinaro, Andrea Cacciato Insilla, Laura Agate, **David Viola**, Luciana Puleo, Gabriele Materazzi, Ivo Marchetti, Paolo Miccoli, Giancarlo Di Coscio, Paolo Vitti, Fulvio Basolo, Rossella Elisei. Eur Thyroid J 2014; 3(suppl 1):73-226. 38th Annual Meeting of the European Thyroid Association. Santiago de Compostela, Spain September 6-10, 2014.
 80. Metastatic thyroid cancer unresponsive to conventional therapy treated with sorafenib “off-label”: an update of our six years of experience. Virginia Cappagli, Valeria Bottici, Eleonora Molinaro, Laura Agate, **David Viola**, Laura Valerio, Paolo Piaggi, Salvatore Mazzeo, Valentina Battaglia, Benedetta Pontillo Contillo, Paolo Vitti, Rossella Elisei. Eur Thyroid J 2014; 3(suppl 1):73-226. 38th Annual Meeting of the European Thyroid Association. Santiago de Compostela, Spain September 6-10, 2014.
 81. The thymic hyperplasia (TH) and biochemical persistence of disease in patients with differentiated thyroid carcinoma. Carla Gambale, Antonio Matrone, Eleonora Molinaro, Laura Agate, Valeria Bottici, Agnese Biagini, **David Viola**, Salvatore Mazzeo, Francesca Bianchi, Federica Brozzi, Paolo Vitti, Rossella Elisei. Eur Thyroid J 2014; 3(suppl 1):73-226. 38th Annual Meeting of the European Thyroid Association. Santiago de Compostela, Spain September 6-10, 2014.
 82. Cabozantinib – current perspectives. R. Elisei, V. Cappagli, **D. Viola**. 14th International workshop on Multiple Endocrine Neoplasia and other rare endocrine tumors, Vienna, Austria, September 25-27 2014.
 83. Elevati valori di BNP sono correlati alla tireotossicosi in pazienti tiroidectomizzati per carcinoma tiroideo. V. Bottici, R. Lari, M.G. Delle Donne, C. Giani, E. Molinaro, L. Agate, **D. Viola**, R. Elisei. XXXII Giornate Italiane della Tiroide/8° Congresso AIT, Milano, 27-29 Novembre 2014.
 84. Il residuo tiroideo post-chirurgico può essere ugualmente ablato con basse attività di 131-I e dopo stimolo con rhTSH in pazienti con DTC a rischio intermedio così come in quelli a basso rischio. A. Matrone, C. Gambale, E. Molinaro, L. Agate, V. Bottici, P. Piaggi, A. Biagini, **D. Viola**, P. Vitti, R. Elisei. XXXII Giornate Italiane della Tiroide/8° Congresso AIT, Milano, 27-29 Novembre 2014.
 85. Riarrangiamento KIF5B/RET in un caso di carcinoma papillare della tiroide variante sclerosante diffusa. C. Giani, **D. Viola**, L. Torregrossa, S. MAzzeo, N. Borelli, A. Matrone, C. Ugolini, G. Fontanini, F. Basolo, P. Vitti, R. Elisei. XXXII Giornate Italiane della Tiroide/8° Congresso AIT, Milano, 27-29 Novembre 2014.
 86. Caratteristiche demografiche e clinico-patologiche delle mutazioni rare di BRAF. **D. Viola**, L. Torregrossa, P. Piaggi, E. Sensi, M. Giordano, C. Giani, F. Basolo, P. Vitti, R. Elisei. XXXII Giornate Italiane della Tiroide/8° Congresso AIT, Milano, 27-29 Novembre 2014.
 87. Diagnostic and therapeutic role of thyroid remnant ablation with low activity of 131-I in patients with low and intermediate risk papillary thyroid carcinoma. L. Agate, F. Bianchi, F. Brozzi, P. Santini, E.

- Molinaro, V. Bottici, **D. Viola**, A. D'Ambrosca, P. Vitti, R. Elisei. 38th National Congress of the Italian Society of Endocrinology. Taormina, May 27-30, 2015.
88. Intermediate risk differentiated thyroid cancer (DTC) patients show the same rate of ablation of low risk DTC patients when treated with 30 mCi of 131-I after stimulation with recombinant human TSH (rhTSH). A. Matrone, C. Gambale, E. Molinaro, L. Agate, V. Bottici, P. Piaggi, A. Biagini, **D. Viola**, F. Bianchi, F. Brozzi, P. Santini, P. Vitti, R. Elisei. 38th National Congress of the Italian Society of Endocrinology. Taormina, May 27-30, 2015.
 89. Carbohydrate antigen 19.9 (Ca 19.9): a prognostic factor for mortality in patients with persistent/recurrent structural medullary thyroid cancer (MTC). L. Lorusso, C. Romei, V. Bottici, **D. Viola**, A. Matrone, P. Piaggi, L. Torregrossa, G. Pellegrini, Vitti, R. Elisei. 38th National Congress of the Italian Society of Endocrinology. Taormina, May 27-30, 2015.
 90. Is the clinical behavior of PTC harbouring rare BRAF mutations different from those harbouring BRAFV600E or BRAF wild type? **D. Viola**, L. Torregrossa, P. Piaggi, E. Sensi, M. Giordano, C. Giani, G. Materazzi, P. Miccoli, P. Vitti, F. Basolo, R. Elisei. 38th National Congress of the Italian Society of Endocrinology. Taormina, May 27-30, 2015.
 91. 5 years follow-up of thyroglobulin (Tg), thyroglobulin antibodies (TgAb) and neck ultrasound (US) in patients with papillary thyroid microcarcinoma (mPTC) treated with total thyroidectomy but not ablated with 131-I. A. Matrone, A. Faranda, E. Molinaro, L. Agate, **D. Viola**, L. Valerio, C. Giani, L. Torregrossa, P. Vitti, R. Elisei. 15th International Thyroid Congress, Orlando, Florida, 18-23 October 2015.
 92. Role of thyroid remnant ablation with low activity of 131-I in patients with low and intermediate risk papillary thyroid carcinoma (PTC). L. Agate, F. Bianchi, F. Brozzi, P. Santini, E. Molinaro, V. Bottici, **D. Viola**, A. D'Ambrosca, P. Vitti, R. Elisei. 15th International Thyroid Congress, Orlando, Florida, 18-23 October 2015.
 93. 5 anni di follow-up di tireoglobulina (Tg), anticorpi antitireoglobulina (AbTg) ed ecografia del collo (nUS) in pazienti affetti da micro carcinoma papillare della tiroide (mPTC) trattati con tiroidectomia totale ma non ablati con 131-I. Matrone A, Faranda A, Molinaro E, Agate A, Bottici V, **Viola D**, Valerio L, Giani C, Torregrossa L, Piaggi P, Vitti P, Elisei R. XXXIII Giornate Italiane della Tiroide/9° Congresso AIT, Udine, 3-5 Dicembre 2015.
 94. Correlazione dell'infiltrazione macrofagica (positività per CD68) con le varianti istologiche più aggressive del carcinoma papillare della tiroide e con la mutazione di BRAF V600E. Puleo L, Romei C, Ugolini C, **Viola D**, Molinaro E, Agate A, Matrone A, Torregrossa L, Basolo F, Elisei R. XXXIII Giornate Italiane della Tiroide/9° Congresso AIT, Udine, 3-5 Dicembre 2015.
 95. Valori di calcitonina basale o stimolata con calcio predittivi di carcinoma midollare della tiroide o iperplasia delle cellule C misurata con metodo immunometrico in chemiluminescenza. Sabini E, Matrone A, Molinaro E, Agate A, **Viola D**, Vitti P, Elisei R. XXXIII Giornate Italiane della Tiroide/9° Congresso AIT, Udine, 3-5 Dicembre 2015.

96. Ristratificazione del rischio di recidiva nei pazienti affetti da carcinoma tiroideo differenziato (DTC): out come clinico di una casistica di “excellent responders”, follow-up a 13 anni. Pieruzzi L, Molinaro E, Agate A, **Viola D**, Vitti P, Elisei R. XXXIII Giornate Italiane della Tiroide/9° Congresso AIT, Udine, 3-5 Dicembre 2015.
97. Significato clinico dell’andamento di tireoglobulina (Tg), anticorpi anti-tireoglobulina (AbTg) ed ecografia del collo (NUS) in pazienti con microcarcinoma papillare della tiroide (mPTC) trattati con tiroidectomia totale ma non ablati con 131-I. Matrone A, Faranda A, Molinaro E, Agate L, Bottici V, **Viola D**, Valerio L, Giani C, Torregrossa L, Piaggi P, Vitti P, Elisei R. Incontri Italiani di Endocrinologia e Metabolismo. Pisa, 19-20 Maggio 2016.
98. Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato. Sabini E, Matrone A, Valerio L, Giani C, Pieruzzi L, Molinaro E, **Viola D**, Agate L, Volterrani D, Mazzeo S, Vitti P, Elisei R. Incontri Italiani di Endocrinologia e Metabolismo. Pisa, 19-20 Maggio 2016.
99. Riarrangiamento KIF5B/RET: carcinoma papillare della tiroide variante sclerosante diffusa metastatico o adenocarcinoma polmonare metastatizzato alla tiroide? Giani C, **Viola D**, Torregrossa L, Mazzeo S, Matrone A, Ugolini C, Fontanini M G, Basolo F, Vitti P, Elisei R. Incontri Italiani di Endocrinologia e Metabolismo. Pisa, 19-20 Maggio 2016.
100. Correlation between the presence of macrophages and the BRAFV600E mutation in differentiated papillary thyroid cancer. L. Puleo, C. Ugolini, **D. Viola**, E. Molinaro, L. Agate, A. Matrone, F. Basolo, P. Vitti, R. Elisei, C. Romei. Eur Thyroid J 2015;Oral Presentations 5(suppl 1):1-194, 2016. 39th Annual Meeting of the European Thyroid Association. Copenhagen, Denmark September 3-6, 2016.
101. 5 years follow-up of thyroglobulin (Tg), thyroglobulin antibodies (TgAb) and neck ultrasound (NUS) in patients with papillary thyroid microcarcinoma (MPTC) treated with total thyroidectomy but not ablated with 131-I. A. Matrone, A. Faranda, E. Molinaro, L. Agate, **D. Viola**, L. Valerio, C. Giani, L. Torregrossa, P. Piaggi, P. Vitti, R. Elisei. Eur Thyroid J 2015;Oral Presentations 5(suppl 1):1-194, 2016. 39th Annual Meeting of the European Thyroid Association. Copenhagen, Denmark September 3-6, 2016.
102. Il titolo degli anticorpi anti-tireoglobulina declina spontaneamente si negativizza dopo 5 anni nella maggior parte dei microcarcinomi papillari trattati chirurgicamente ma non con terapia radio metabolica. A. Matrone, E. Molinaro, L. Agate, V. Bottici, **D. Viola**, L. Valerio, L. Lorusso, A. Faranda, P. Piaggi, P. Vitti, R. Elisei. X Congresso Associazione Italiana della Tiroide. Cagliari 15-17 Dicembre 2016.
103. La proteinuria è un inevitabile evento avverso tardivo di Cabozantinib di difficile gestione clinica. V. Cappagli, **D. Viola**, V. Bottici, E. Molinaro, L. Agate, L. Lorusso, D. Moriconi, M. F. Egidi, R. Elisei. XXXIV Giornate Italiane della Tiroide (10° Congresso Associazione Italiana della Tiroide). Cagliari, 15-17 Dicembre 2016.

104. Proteinuria is a late onset adverse event in patients treated with Cabozantinib: a single center experience. V. Cappagli, **D. Viola**, V. Bottici, E. Molinaro, L. Agate, L. Lorusso, D. Moriconi, M. F. Egidi, R. Elisei. 39° Congresso Nazionale Società Italiana di Endocrinologia, Roma, 21-24 Giugno 2017.
105. Long-term follow-up of children and adolescents affected by differentiated thyroid cancer: consequences of surgical treatment and radioiodine treatment. V. Bottici, L. Agate, P. Fabbrini, F. Bianchi, E. Molinaro, **D. Viola**, G. Materazzi, F. Basolo, P. Vitti, R. Elisei. 39° Congresso Nazionale Società Italiana di Endocrinologia, Roma, 21-24 Giugno 2017.
106. Thyroglobulin antibodies (TgAb) titer spontaneously decrease until the negativization or stabilization in most of cases of papillary thyroid microcarcinoma (MPTC) treated with total thyroidectomy but not ablated with 131-I. A. Matrone, E. Molinaro, L. Agate, V. Bottici, **D. Viola**, L. Valerio, L. Lorusso, A. Faranda, P. Piaggi, P. Vitti, R. Elisei. 39° Congresso Nazionale Società Italiana di Endocrinologia, Roma, 21-24 Giugno 2017.
107. Are the clinical pathological features and aggressiveness of differentiated thyroid microcarcinoma changed over the years? **D. Viola**, L. Agate, E. Molinaro, V. Bottici, L. Lorusso, A. Matrone, L. Torregrossa, F. Basolo, G. Materazzi, P. Vitti, R. Elisei. 39° Congresso Nazionale Società Italiana di Endocrinologia, Roma, 21-24 Giugno 2017.
108. Active surveillance in papillary thyroid microcarcinomas: preliminary data of a single-center observational trial. L. Pieruzzi, E. Sabini, A. Matrone, L. Agate, V. Bottici, **D. Viola**, C. Marocchi, P. Vitti, R. Elisei, E. Molinaro. 39° Congresso Nazionale Società Italiana di Endocrinologia, Roma, 21-24 Giugno 2017.
109. Active surveillance in papillary thyroid microcarcinomas (PMCS): a 2 years follow-up (FU) at a single center. L. Pieruzzi, A. Matrone, L. Agate, V. Bottici, D. Viola, C. Marocchi, P. Vitti, R. Elisei, E. Molinaro. 40th Annual Meeting of the European Thyroid Association. Belgrade, Serbia September 9-12, 2017. Eur Thyroid J 2017; 6 (suppl 1): 23-118.
110. KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC). C. Giani, D. Viola, R. Ciampi, C. Romei, C. Ugolini, E. Molinaro, L. Agate, S. Mazzeo, A. Chella, G. Fontanini, F. Basolo, R. Elisei. 40th Annual Meeting of the European Thyroid Association. Belgrade, Serbia September 9-12, 2017. Eur Thyroid J 2017; 6 (suppl 1): 23-118.
111. Thyroglobulin antibodies (TgAb) titer spontaneously decrease until the negativization or stabilization in most of cases of papillary thyroid microcarcinoma (mPTC) treated with total thyroidectomy but not ablated with 131-I. A. Matrone, E. Molinaro, L. Agate, V. Bottici, D. Viola, L. Valerio, L. Lorusso, A. Faranda, P. Piaggi, P. Vitti, R. Elisei. 40th Annual Meeting of the European Thyroid Association. Belgrade, Serbia September 9-12, 2017. Eur Thyroid J 2017; 6 (suppl 1): 23-118.
112. Osteonecrosi della mandibola (ONJ) in paziente affetto da carcinoma follicolare della tiroide metastatico, iodorefrattario in terapia con sorafenib e acido zoledronico. L. Pieruzzi, A. Matrone, L.

- Agate, V. Bottici, **D. Viola**, C. Marcocci, P. Vitti, R. Elisei, E. Molinaro. 11° Congresso Nazionale Società Italiana della Tiroide (XXXV Giornate Italiane della Tiroide), Torino, 30 Novembre-2 Dicembre 2017.
113. Impatto dei valori di tireoglobulina post-operatoria, ecografia del collo e scintigrafia totale corporea post-ablazione con 131-I sulla ristrutturazione del rischio di recidiva. C. Gambale, A. Matrone, L. Torregrossa, E. Molinaro, L. Agate, **D. Viola**, F. Bianchi, P. Santini, F. Brozzi, P. Vitti, R. Elisei. 11° Congresso Nazionale Società Italiana della Tiroide (XXXV Giornate Italiane della Tiroide), Torino, 30 Novembre-2 Dicembre 2017.
114. Fattori di rischio, fattori predittori di guarigione e miglior trattamento delle recidive linfonodali di carcinoma tiroideo. **D. Viola**, L. Bedini, G. Materazzi, L. De Napoli, F. Bianchi, E. Molinaro, L. Agate, P. Vitti, R. Elisei. 11° Congresso Nazionale Società Italiana della Tiroide (XXXV Giornate Italiane della Tiroide), Torino, 30 Novembre-2 Dicembre 2017.
115. Sorveglianza attiva nei microcarcinomi papillari tiroidei (mPTC): dati preliminari dello studio osservazionale di un singolo centro. L. Pieruzzi, E. Sabini, A. Matrone, L. Agate, V. Bottici, **D. Viola**, C. Marcocci, P. Vitti, R. Elisei, E. Molinaro. 11° Congresso Nazionale Società Italiana della Tiroide (XXXV Giornate Italiane della Tiroide), Torino, 30 Novembre-2 Dicembre 2017.
116. Rilevanza dell'integrità della capsula tumorale nella prognosi del carcinoma papillare variante classica (CVPTC) e follicolare (FVPTC). C. Giani, L. Torregrossa, C. Ugolini, C. Romei, E. Molinaro, **D. Viola**, L. Agate, P. Piaggi, G. Materazzi, F. Basolo, P. Vitti, R. Elisei. 11° Congresso Nazionale Società Italiana della Tiroide (XXXV Giornate Italiane della Tiroide), Torino, 30 Novembre-2 Dicembre 2017.
117. The integrity of tumor capsule identifies a subgroup of indolent cases not only among the follicular (FVPTC) but also in classic variant of papillary thyroid cancer (CVPTC). C. Giani, V. Cappagli, L. Torregrossa, C. Ugolini, C. Romei, D. Viola, E. Molinaro, F. Basolo, P. Vitti, R. Elisei. Oral communication at the ENDO 2018 (Chicago, Illinois), March 17-20, 2018. Endocrine Reviews, Volume 39, Issue 2 Supplement, April 2018.
118. Recidiva di carcinoma tiroideo diagnosticato con l'aumento del titolo anticorpale (AbTg) dopo 10 anni dal trattamento iniziale. **D. Viola**, L. Agate, E. Molinaro, V. Bottici, L. Lorusso, L. Torregrossa, F. Latrofa, P. Vitti, R. Elisei. Incontri Italiani di Endocrinologia e Metabolismo, Bari, 10-11 Maggio 2018.
119. Terapia con Lenvatinib nel trattamento del carcinoma tiroideo differenziato radioiodio-refrattario in progressione: analisi di 74 casi seguiti in un singolo centro. C. Giani, L. Valerio, L. Pieruzzi, L. Agate, **D. Viola**, V. Bottici, L. Lorusso, V. Cappagli, L. Puleo, A. Matrone, S. Mazzeo, B. Pontillo Contillo, A. Ribechini, P. Vitti, E. Molinaro, R. Elisei. Incontri Italiani di Endocrinologia e Metabolismo, Bari, 10-11 Maggio 2018.
120. Impatto della terapia radiometabolica ablativa (RRA) sulla ristrutturazione del rischio di recidiva nel follow up a breve termine dei pazienti con carcinoma differenziato della tiroide (DTC). C.

- Gambale, A. Matrone, E. Molinaro, L. Agate, **D. Viola**, L. Lorusso, C. Giani, V. Cappagli, V. Bottici, F. Bianchi, P. Vitti, R. Elisei. Incontri Italiani di Endocrinologia e Metabolismo, Bari, 10-11 Maggio 2018.
121. Impatto della modalità di preparazione alla terapia radiometabolica con 131-I in pazienti con carcinoma differenziato della tiroide. E. Addante, C. Giani, F. Bianchi, L. Agate, **D. Viola**, P. Vitti, R. Elisei, E. Molinaro. Incontri Italiani di Endocrinologia e Metabolismo, Bari, 10-11 Maggio 2018.
 122. Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre. 41st Annual Meeting of the European Thyroid association. C Giani, L Valerio, L Pieruzzi, L Agate, **D Viola**, V Bottici, P Piaggi, L Lorusso, V Cappagli, L Puleo, A Matrone, S Mazzeo, B Pontillo Contillo, A Ribechini, P Vitti, E Molinaro, R Elisei. Newcastle, 15-18 Settembre 2018.
 123. Mutational profile of a large series of sporadic medullary thyroid carcinomas by next generation targeted sequencing. R Ciampi, C Romei, A Tacito, T Ramone, **D Viola**, V Bottici, **L Agate**, E Molinaro, L Torregrossa, C Ugolini, F Basolo, R Elisei. 41st Annual Meeting of the European Thyroid association. Newcastle, 15-18 Settembre 2018.
 124. Impact of the stimulation method used for 131I-therapy in patients with differentiated thyroid cancer. E Addante, C Giani, F Bianchi, F Brozzi, P Santini, L Agate, **D Viola**, V Bottici, P Vitti, R Elisei, E Molinaro. 41st Annual Meeting of the European Thyroid association. Newcastle, 15-18 Settembre 2018.
 125. Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients. A Matrone, C Gambale, L Torregrossa, F Bianchi, L Valerio, **D Viola**, L Agate, E Molinaro, F Basolo, P Vitti, R Elisei. 41st Annual Meeting of the European Thyroid association. Newcastle, 15-18 Settembre 2018.
 126. NGS Target Sequencing of a Large Series of Sporadic Medullary Thyroid Carcinomas R Ciampi, C Romei, A Tacito, T Ramone, **D Viola**, V Bottici, L Agate, E Molinaro, L Torregrossa, C Ugolini, F Basolo, R Elisei. 88th Annual Meeting of the American Thyroid Association, Washington, 3-7 Ottobre 2018.
 127. Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). A Matrone, C Gambale, L Torregrossa, F Bianchi, L Valerio, **D Viola**, L Agate, E Molinaro, F Basolo, P Vitti, R Elisei. 88th Annual Meeting of the American Thyroid Association, Washington, 3-7 Ottobre 2018.
 128. RET genetic screening re-defines the prevalence of Multiple Endocrine Neoplasia type 2A, 2B and Familial form of Medullary Thyroid Cancer. C Romei, A Tacito, T Ramone, R Ciampi, V Bottici, V Cappagli, **D Viola**, L Agate, E Molinaro, R Elisei. 88th Annual Meeting of the American Thyroid Association, Washington, 3-7 Ottobre 2018.
 129. Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma

treated with Lenvatinib. C Giani, L Valerio, L Pieruzzi, L Agate, **D Viola**, V Bottici P Piaggi, L Lorusso, V Cappagli, L Puleo, A Matrone, S Mazzeo, B Pontillo Contillo, A Ribechini, P Vitti, E Molinaro, R Elisei. 88th Annual Meeting of the American Thyroid Association, Washington, 3-7 Ottobre 2018.

130. Risk Factors, outcome predictors and best treatment for differentiated thyroid cancer lymph node recurrence. **D Viola**, L Bedini, G Materazzi, E Molinaro, L Agate, C Ugolini, F Basolo, P Vitti, R Elisei. 88th Annual Meeting of the American Thyroid Association, Washington, 3-7 Ottobre 2018.

I authorise the processing of my personal data for personnel research and selection purposes under the Italian D.Lgs. n.196 of 30/06/2003

Dr. David Viola